MedPath

The effect of tofogliflozin on body fat volume

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000036013
Lead Sponsor
Tokushima University Graduate School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

Hypersensitivity to canagliflozin, Complicated with sever ketoacidosis, diabetic coma, Type 1 diabetes, Complicated with severe infection, sever trauma

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Epicardial Adipose Tissue Thickness,HbA1c6 month after the treatment
Secondary Outcome Measures
NameTimeMethod
body weight, voluem of visceral fat, subcutaneous fat, skeletal muscle
© Copyright 2025. All Rights Reserved by MedPath